Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Laurus Labs zooms 53% in Q1FY27; logs sharpest quarterly rally in 5 years
Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.
Aurobindo Pharma among 9 mid-cap stocks to hit 52-week highs & rally up to 20% in a month
The Sensex fell 372 points on Monday, but nine BSE Midcap stocks touched fresh 52-week highs, signalling resilient investor confidence. Bank of Maharashtra, Thermax, Bharat Forge, Oracle Financial Services and Laurus Labs were among the key outperformers despite broader market weakness.
Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improve
Laurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The company is investing ₹3,000 crore in expanding capacities, particularly for high-value CDMO services, which are projected to double their revenue share by 2030. Analysts are optimistic, raising earnings forecasts and maintaining a 'BUY' rating, anticipating continued growth across its diverse segments.
GE Vernova among 9 midcap stocks hit 52-week highs, rally up to 25% in a month
Despite a sharp fall in the Sensex, nine BSE MidCap stocks including GE Vernova, Bharat Forge and Laurus Labs hit fresh 52-week highs, gaining up to 25% in a month on strong investor interest.
Laurus Labs Ltd soars 2.73%, Gains for third straight session
Laurus Labs Ltd is quoting at Rs 1475.1, up 2.73% on the day as on 12:49 IST on the NSE. The stock is up 120.31% in last one year as compared to a 4.46% fall in NIFTY and a 15.59% fall in the Nifty Pharma index.
Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM Financial
JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as high-probability additions from the Small Cap Index, while Ather Energy and SAIL are medium-probability candidates. SBI Card faces a high probability of exclusion. These potential changes could lead to substantial passive fund inflows into India, estimated around $3.2 billion, impacting institutional investors.
August MSCI Rejig Could Trigger Over Rs 30,000 Crore Inflows Into India; Laurus Labs, Biocon Lead Race
Among the likely beneficiaries, Laurus Labs and Biocon have been assigned a high probability of moving from the MSCI India Small Cap Index to the MSCI India Standard Index.
Sai Life, Laurus Labs hit new highs; stocks rally up to 40% in 6 months
Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends 3 stocks to buy today amid RBI policy - 5 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 5 June 2026 - BSE, Laurus Labs and Exide Industries shares.
Market Trading Guide: NMDC among two stock recommendations for Tuesday
Indian benchmark indices extended losses for a fourth straight session as FII selling and geopolitical concerns hurt sentiment. Amid the weakness, analysts recommend NMDC and Laurus Labs, citing bullish chart patterns, strong momentum, breakout formations and favorable technical indicators for further upside.
Laurus Labs Ltd spurts 1.14%, up for third straight session
Laurus Labs Ltd is quoting at Rs 1389.5, up 1.14% on the day as on 12:49 IST on the NSE. The stock is up 127.6% in last one year as compared to a 3.32% fall in NIFTY and a 15.48% fall in the Nifty Pharma index.
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?
Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business improvements, better margins, and strong earnings, the pharma major's market cap surged. Analysts see further upside but advise caution with stop losses due to the steep rise.